TY - JOUR
T1 - A critical role for enhanced TGF-α and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease
AU - Cozzolino, Mario
AU - Lu, Yan
AU - Sato, Tetsuhiko
AU - Yang, Jing
AU - Suarez, Ignacio Gonzalez
AU - Brancaccio, Diego
AU - Slatopolsky, Eduardo
AU - Dusso, Adriana S.
PY - 2005/11
Y1 - 2005/11
N2 - The parathyroid hyperplasia secondary to kidney disease is associated with enhanced expression of the growth promoter transforming growth factor-α (TGF-α). TGF-α stimulates growth through activation of its receptor, the epidermal growth factor receptor (EGFR), normally expressed in the parathyroid glands. Because enhanced coexpression of TGF-α and EGFR causes aggressive cellular growth, these studies utilized highly specific inhibitors of EGFR tyrosine kinase, a step mandatory for TGF-α-induced EGFR activation, to assess the contribution of growth signals from enhanced expression of TGF-α exclusively or both TGF-α and EGFR to the rapid parathyroid growth induced by kidney disease and exacerbated by high-phosphorus (P) and low-calcium (Ca) diets in rats. The enhancement in parathyroid gland weight and proliferating activity (proliferating cell nuclear antigen/Ki67) induced by kidney disease and aggravated by either high P or low Ca intake, within the first week after 5/6 nephrectomy, in rats, coincided with simultaneous increases (2- to 3-fold) in TGF-α and EGFR content. Conversely, prevention of the increases in both TGF-α and EGFR paralleled the efficacy of either P restriction or high-Ca intake in ameliorating uremia-induced parathyroid hyperplasia. More importantly, suppression of TGF-α/EGFR signaling, through prophylactic administration of potent and highly selective inhibitors of ligand-induced EGFR activation, completely prevented both high-P- and low-Ca-induced parathyroid hyperplasia as well as TGF-α self-upregulation. Thus enhanced parathyroid TGF-α/EGFR expression, self-upregulation, and growth signals occur early in kidney disease, are aggravated by low-Ca and high-P intake, and constitute the main pathogenic mechanism of the severity of parathyroid hyperplasia.
AB - The parathyroid hyperplasia secondary to kidney disease is associated with enhanced expression of the growth promoter transforming growth factor-α (TGF-α). TGF-α stimulates growth through activation of its receptor, the epidermal growth factor receptor (EGFR), normally expressed in the parathyroid glands. Because enhanced coexpression of TGF-α and EGFR causes aggressive cellular growth, these studies utilized highly specific inhibitors of EGFR tyrosine kinase, a step mandatory for TGF-α-induced EGFR activation, to assess the contribution of growth signals from enhanced expression of TGF-α exclusively or both TGF-α and EGFR to the rapid parathyroid growth induced by kidney disease and exacerbated by high-phosphorus (P) and low-calcium (Ca) diets in rats. The enhancement in parathyroid gland weight and proliferating activity (proliferating cell nuclear antigen/Ki67) induced by kidney disease and aggravated by either high P or low Ca intake, within the first week after 5/6 nephrectomy, in rats, coincided with simultaneous increases (2- to 3-fold) in TGF-α and EGFR content. Conversely, prevention of the increases in both TGF-α and EGFR paralleled the efficacy of either P restriction or high-Ca intake in ameliorating uremia-induced parathyroid hyperplasia. More importantly, suppression of TGF-α/EGFR signaling, through prophylactic administration of potent and highly selective inhibitors of ligand-induced EGFR activation, completely prevented both high-P- and low-Ca-induced parathyroid hyperplasia as well as TGF-α self-upregulation. Thus enhanced parathyroid TGF-α/EGFR expression, self-upregulation, and growth signals occur early in kidney disease, are aggravated by low-Ca and high-P intake, and constitute the main pathogenic mechanism of the severity of parathyroid hyperplasia.
KW - Epidermal growth factor receptor
KW - Growth arrest
KW - Renal failure
KW - Secondary hyperparathyroidism
KW - Tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=26844544783&partnerID=8YFLogxK
U2 - 10.1152/ajprenal.00167.2005
DO - 10.1152/ajprenal.00167.2005
M3 - Article
C2 - 15998841
AN - SCOPUS:26844544783
SN - 0363-6127
VL - 289
SP - F1096-F1102
JO - American Journal of Physiology - Renal Physiology
JF - American Journal of Physiology - Renal Physiology
IS - 5 58-5
ER -